Keryx Biopharmaceuticals Inc (KERX)

4.57
NASDAQ : Health Care
Prev Close 4.63
Day Low/High 4.53 / 4.80
52 Wk Low/High 2.80 / 7.80
Avg Volume 1.70M
Exchange NASDAQ
Shares Outstanding 105.90M
Market Cap 490.29M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering breakout trades.

SHAREHOLDER ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors Of Important Deadline In Class Action - KERX

SHAREHOLDER ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors Of Important Deadline In Class Action - KERX

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Keryx Biopharmaceuticals, Inc.

Cohen Milstein Sellers & Toll PLLC Announces The Investigation Of Keryx Biopharmaceuticals, Inc.

Cohen Milstein Sellers & Toll PLLC Announces The Investigation Of Keryx Biopharmaceuticals, Inc.

Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Keryx Biopharmaceuticals, Inc.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Keryx Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Keryx Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

Today's Perilous Reversal Stock: Keryx Biopharmaceuticals (KERX)

Today's Perilous Reversal Stock: Keryx Biopharmaceuticals (KERX)

Trade-Ideas LLC identified Keryx Biopharmaceuticals (KERX) as a "perilous reversal" (up big yesterday but down big today) candidate

IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC (the "Firm") announces that a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Keryx Biopharmaceuticals Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Keryx Biopharmaceuticals Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Keryx Biopharmaceuticals, Inc.

Insider Trading Alert - CFFI, KERX And INCY Traded By Insiders

Insider Trading Alert - CFFI, KERX And INCY Traded By Insiders

Stocks with insider trader activity include CFFI, KERX and INCY

Keryx Biopharmaceuticals (KERX) Marked As A Dead Cat Bounce Stock

Keryx Biopharmaceuticals (KERX) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Keryx Biopharmaceuticals (KERX) as a "dead cat bounce" (down big yesterday but up big today) candidate

SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. And Encourages Investors With Losses To Contact The Firm

SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. And Encourages Investors With Losses To Contact The Firm

Goldberg Law PC (the "Firm") announces that a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc.

Keryx Biopharmaceuticals (KERX) Stock Continues to Fall on Disrupted Production

Keryx Biopharmaceuticals (KERX) Stock Continues to Fall on Disrupted Production

Keryx Biopharmaceuticals (KERX) stock is still declining Tuesday afternoon after the company's only approved medication experienced disruptions in production.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Keryx Biopharmaceuticals Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Keryx Biopharmaceuticals Inc.

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Keryx Biopharmaceuticals Inc.

IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces An Investigation Of Keryx Biopharmaceuticals Inc. And Advises Investors With Losses To Contact The Firm

IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces An Investigation Of Keryx Biopharmaceuticals Inc. And Advises Investors With Losses To Contact The Firm

Lundin Law PC ( http://lundinlawpc.com/) announces it is investigating claims against Keryx Biopharmaceuticals Inc.

Noteworthy Monday Option Activity: KERX, DATA, GDDY

Noteworthy Monday Option Activity: KERX, DATA, GDDY

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Keryx Biopharmaceuticals Inc. , where a total volume of 6,351 contracts has been traded thus far today, a contract volume which is representative of approximately 635,100 underlying shares (given that every 1 contract represents 100 underlying shares).

Oversold Conditions For Keryx Biopharmaceuticals (KERX)

Oversold Conditions For Keryx Biopharmaceuticals (KERX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

3 Stocks Underperforming Today In The Drugs Industry

3 Stocks Underperforming Today In The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry lower today.